Clinical and Echocardiographic Study of Mitral Valve Repair in A Tertiary Center in Oman

Document Type : Original Article


Department of Cardiology, National Heart Center Royal Hospital, Muscat, Oman.


Introduction: In recent years, mitral valve (MV) repair has become the procedure of choice for treating isolated mitral regurgitation (MR). The aim of this study was to evaluate immediate and long-term clinical and echocardiographic results of MV repair performed at a tertiary hospital in Oman.
Materials and Methods: The study population consisted of patients with severe MR above 18years of age who had isolated MV repair between 2006 and 2016 at Royal Hospital, Oman. Retrospective observational study. Primary Endpoints: 1-year freedom from reoperation, recurrence of severe MR and mortality. Secondary Endpoints: Five-year echocardiographic recurrence of severe MR, ejection fraction (EF), NYHA class and mortality.
Results: The case records of 351 patients with MR who had MV surgery in Royal Hospital were reviewed. A total of 89 patients had isolated MV repair surgery with follow up 1 year. The etiology of mitral disease was degenerative in 58.42%, rheumatic in 20.22%, post endocarditis in 12.35%, congenital 5.61% and ischemic MR in 3.37%. Operative mortality was 2.24% (2/89). Pre-operative NHYA class III/IV was noted in 62.92% of patients (56/89). All the patients had an EF of > 60%.  Among the 87 patients followed up for one-year, 95.40 % (83/87) of patients were free from reoperation. Four patients (4.59%) had recurrence of severe MR needing MV replacement surgery. Of the 87 patients, 56 patients were followed in our institute for 5 years had demonstrated trivial to mild MR in 73.2% (41/56) moderate MR in 16.07% (9/56), and severe MR in 10.07% (6/56) of patients though 83.92% (47/56) patients were in NYHA class I. Majority of grade 3 (10.71%) and 4 MR (8.92%) occurred in patients with rheumatic etiology who underwent MV repair. Ejection fraction remained > 60% in 89.28% patients. There was no mortality at 5 years among the 56 patients followed-up.
Conclusions: MV repair in a tertiary center in Oman showed favorable early and one-year results as regards mortality, freedom from reoperation and recurrence of significant MR. Those followed-up at five years, majority of patients were asymptomatic though echocardiographic recurrence of moderate and severe MR was high predominantly in patients with rheumatic etiology.


  1. A McNeely C, M Vassileva C. Long-term outcomes of mitral valve repair versus replacement for degenerative disease: a systematic review. Current cardiology reviews. 2015 May 1;11(2):157-62.
  2. Gammie JS, Sheng S, Griffith BP, Peterson ED, Rankin JS, O'Brien SM, et al. Trends in mitral valve surgery in the United States: results from the Society of Thoracic Surgeons Adult Cardiac Database. The Annals of thoracic surgery. 2009 May 1;87(5):1431-9.
  3. Suri RM, Schaff HV, Dearani JA, Sundt III TM, Daly RC, Mullany CJ, et al. Survival advantage and improved durability of mitral repair for leaflet prolapse subsets in the current era. The Annals of thoracic surgery. 2006 Sep 1;82(3):819-26.
  4. Stevens LM, Basmadjian AJ, Bouchard D, El‐Hamamsy I, Demers P, Carrier M, et al. Late echocardiographic and clinical outcomes after mitral valve repair for degenerative disease. Journal of cardiac surgery. 2010 Jan;25(1):9-15.
  5. McClure RS, Athanasopoulos LV, McGurk S, Davidson MJ, Couper GS, Cohn LH. One thousand minimally invasive mitral valve operations: early outcomes, late outcomes, and echocardiographic follow-up. The Journal of thoracic and cardiovascular surgery. 2013 May 1;145(5):1199-206.
  6. Yoo JS, Kim JB, Jung SH, Choo SJ, Chung CH, Lee JW. Echocardiographic assessment of mitral durability in the late period following mitral valve repair: minithoracotomy versus conventional sternotomy. The Journal of Thoracic and Cardiovascular Surgery. 2014 May 1;147(5):1547-52.
  7. Zoghbi WA, Adams D, Bonow RO, Enriquez-Sarano M, Foster E, Grayburn PA, et al. Recommendations for noninvasive evaluation of native valvular regurgitation: a report from the American Society of Echocardiography developed in collaboration with the Society for Cardiovascular Magnetic Resonance. Journal of the American Society of Echocardiography. 2017 Apr 1;30(4):303-71.
  8. Lancellotti P, Tribouilloy C, Hagendorff A, Popescu BA, Edvardsen T, Pierard LA, et al. Recommendations for the echocardiographic assessment of native valvular regurgitation: an executive summary from the European Association of Cardiovascular Imaging. European Heart Journal–Cardiovascular Imaging. 2013 Jul 1;14(7):611-44.
  9. Baumgartner H, Falk V, Bax JJ, De Bonis M, Hamm C, Holm PJ, et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. European heart journal. 2017;38(36):2739-86.
  10. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin III JP, Fleisher LA, et al. 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2017 Jun 20;135(25):e1159-95.
  11. Daneshmand MA, Milano CA, Rankin JS, Honeycutt EF, Swaminathan M, Shaw LK, et al. Mitral valve repair for degenerative disease: a 20-year experience. The Annals of Thoracic Surgery. 2009 Dec 1;88(6):1828-37.
  12. Zhou YX, Leobon B, Berthoumieu P, Roux D, Glock Y, Mei YQ, et al. Long-term outcomes following repair or replacement in degenerative mitral valve disease. The Thoracic and cardiovascular surgeon. 2010 Oct;58(07):415-21.
  13. Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J, et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease: developed by the Task Force for the management of valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). European heart journal. 2022 Feb 14;43(7):561-632.
  14. Kaneyuki D, Nakajima H, Asakura T, Yoshitake A, Tokunaga C, Tochii M, et al. Recurrent mitral regurgitation after mitral valve repair for bileaflet lesions in the modern era. Journal of Cardiothoracic Surgery. 2019 Dec;14:1-7.
  15. Farivar RS, Shernan SK, Cohn LH. Late rupture of polytetrafluoroethylene neochordae after mitral valve repair. The Journal of Thoracic and Cardiovascular Surgery. 2009 Feb 1;137(2):504-6.
  16. Shahin1ABDEF GM, van der Heijden2ACDE GJ, Kelder1ACDE JC, Boulaksil1ABF M, Knaepen1ADE PJ, Six3ACDEF AJ. Long-term follow-up of mitral valve repair: a single-center experience. Med Sci Monit. 2006;12(7):314.
  17. DiBardino DJ, ElBardissi AW, McClure RS, Razo-Vasquez OA, Kelly NE, Cohn LH. Four decades of experience with mitral valve repair: analysis of differential indications, technical evolution, and long-term outcome. The Journal of Thoracic and Cardiovascular Surgery. 2010 Jan 1;139(1):76-84.
  18. Yau TM, El-Ghoneimi YA, Armstrong S, Ivanov J, David TE. Mitral valve repair and replacement for rheumatic disease. The Journal of thoracic and cardiovascular surgery. 2000 Jan 1;119(1):53-61.
  19. Vassileva CM, Mishkel G, McNeely C, Boley T, Markwell S, Scaife S, et al. Long-term survival of patients undergoing mitral valve repair and replacement: a longitudinal analysis of Medicare fee-for-service beneficiaries. Circulation. 2013 May 7;127(18):1870-6.